The pharmaceutical firm Esteve takes motion | Business | EUROtoday

There is a time to look, and a time to purchase. The Catalan pharmacist Esteve, specialised in medicines for neurological and psychiatric pathologies, in opposition to ache and likewise within the space of ​​ophthalmology, has been trying and learning lots in latest months, making ready to discover a good time to buy groceries. This second appears to reach this yr in 2024. The firm, one of many representatives of the highly effective Catalan pharmaceutical sector made up of household firms, took a leap ahead final yr, when the household introduced in a German investor, Lubea, which turned with 26% of the property. “We needed more capital to continue growing, and now, with this money in the bank, we can undertake mergers, acquisitions and expand the portfolio to make Esteve stronger,” says the pharmaceutical firm's CEO, Staffan Schüberg, in an interview on the firm's headquarters in Barcelona.

In actuality, Esteve's soar began longer in the past. This firm is, together with Uriach, Ferrer, Almirall and Grifols, one of many historic firms of the Catalan pharmaceutical trade. All of them, some compelled by circumstances and others with a extra strategic imaginative and prescient, have undertaken a professionalization course of in order that the proprietor household leaves administration within the fingers of exterior executives.

In 2018 the corporate employed Schüberg for the place of CEO, changing Albert Esteve, and the brand new government had an necessary mission: to redefine the strategic plan, give attention to specialised drugs and for the corporate to personal its merchandise, specializing in efforts in innovation. The following yr, the pharmaceutical firm divested from its generic division, acquired the German Riemser in 2020 and started to enter new European markets, equivalent to Italy and Portugal.

In this fashion, the leap was ready, however another enhance was lacking: rising capital. In May 2023, Schüberg introduced that Lubea was coming into the capital of Esteve Healthcare (consists of the pharmaceutical division and the CMO division, which is devoted to manufacturing lively components for different laboratories) with 26%. The relaxation remained within the fingers of the proprietor household, which for its half continues to manage 100% of Corporación Químico Farmacéutica Esteve, the funding firm that owns 50% of Esteve Teijin Healthcare, 50% of Isdin and 15% of Hangzhou. Jiuyuan Gene Engineering.

In this race to achieve dimension, the pharmaceutical firm doesn’t rule out going public sooner or later, though for now there are not any plans on the desk. “We have to do what is best to be stable in the long term. Going public could be part of this path. But now we have the capital, the property and the momentum to do business. In a couple of years things may be different,” says the CEO.

The change of path has already begun to bear fruit. In 2022, the corporate had a turnover of 642.4 million euros (15% greater than the earlier yr), achieved 125 million gross working revenue (ebitda) and a internet revenue of 78.3 million, quadrupling what it obtained in 2018, when The new technique started. Schüberg explains that the yr 2023, whose accounts should not but public, has additionally given good outcomes: “We have grown more than 10%, we are above 700 million euros in turnover and an EBITDA margin of around 20% ”. The lively ingredient manufacturing division is a kind of that exhibits essentially the most energy. “Growth, in the future, will definitely be here, although it will depend on demand, since what we do in this division is produce for other companies,” explains Shüberg, who provides: “So we’re seeing extra progress within the CMO division , however the specialty medicines division can be rising and catching up. The factor is that we will solely develop there by means of acquisitions, mergers and increasing portfolios of merchandise”.

In full growth, the moment also seems right to acquire companies. “In 2023 there was a lot of mismatch between sales and purchase opportunities, due to price expectations. Now that interest rates are stabilizing, I think we will see more deals close.” In the case of Esteve, its goal is to become an “important player in Europe” in the three therapeutic areas it has in its catalog: “In the future we will specialize in one or two of these therapeutic areas, but it will be the business opportunities those that show us the way of which areas to choose,” he points out. They are studying all options. “We are looking at opportunities of all kinds, the important thing is that they fit the criteria regarding financial strength, geographical location, and are clear in which therapeutic areas they work in,” adds the CEO: “Most likely, the acquisition will be of a series of companies.”

Investment in China

Esteve, whose historically best-known products are Afterbite, Dormidina or Triptomax, has three factories and a chemical development center in Catalonia, and also produces in Mexico and China. In this last factory, of active ingredients, it has had to invest 50 million to move it because the Chinese Government wants to develop a residential area where it was located until now. And at the Celrà plant (Girona), the company plans to make investments this year to expand its capacity by 50 cubic meters.

Another of its objectives this year is to launch Velyntra, a medication to treat acute pain more quickly, on the market. This month, the European Medicines Agency recognized the clinical value of this innovation, which means that it can now be financed, then put a price on it and have it enter the nomenclature. This product is an example of what Esteve does and what it describes as “incremental innovation”: adding two generated molecules, generating a product that can be more effective than the originals.

Follow all the information Economy y Business in Facebook y Xor in our newsletter semanal